RTP Mobile Logo
Submitted by web@researchtop... on Fri, 03/08/2019 - 13:34
LCU119

Interview with Suresh S Ramalingam, MD

Track 1: Mechanisms of resistance to osimertinib and management of non-small cell lung cancer (NSCLC) with EGFR tumor mutations in patients who experience disease progression on first-line osimertinib
Track 2: Results of the Phase III IMpower150 trial: Atezolizumab and chemotherapy with or without bevacizumab versus bevacizumab and chemotherapy for chemotherapy-naïve metastatic nonsquamous NSCLC
Track 3: Role of bevacizumab in combination with EGFR tyrosine kinase inhibitors (TKIs) for patients with NSCLC and EGFR tumor mutations
Track 4: Emerging data with novel TKIs for patients with NSCLC and MET gene amplifications
Track 5: Incidence and clinical significance of MET amplifications and MET exon 14 mutations
Track 6: Use of liquid biopsies to detect mutations in patients with lung cancer
Track 7: FLAURA study results: Osimertinib versus erlotinib or gefitinib as first-line therapy for advanced NSCLC with an EGFR tumor mutation
Track 8: Ongoing evaluation of EGFR TKIs for Stage III NSCLC
Track 9: Perspective on the use of osimertinib in the adjuvant setting
Track 10: Case: A 62-year-old man and never smoker with Stage IV NSCLC and an EGFR exon 19 deletion receives osimertinib as first-line treatment
Track 11: Response to osimertinib in patients with brain metastases
Track 12: Case: A 44-year-old man and never smoker with metastatic NSCLC and an ALK rearrangement receives alectinib after disease progression on crizotinib with an anti-PD-1 antibody
Track 13: ALTA-1L: A Phase III trial evaluating brigatinib versus crizotinib for advanced NSCLC with an ALK rearrangement
Track 14: Efficacy and tolerability of lorlatinib in patients with NSCLC and an ALK rearrangement
Track 15: Case: A 52-year-old woman and nonsmoker with metastatic NSCLC and a BRAF V600E tumor mutation receives dabrafenib and trametinib as second-line therapy
Track 16: Use of targeted therapy as first-line treatment for patients with NSCLC
Track 17: Case: A 58-year-old man with locally advanced squamous cell carcinoma of the lung receives durvalumab as consolidation therapy after chemoradiation therapy
Track 18: Overall survival with the addition of durvalumab to chemoradiation therapy for patients with Stage III NSCLC
Track 19: Pulmonary toxicity associated with durvalumab
Track 20: Ongoing investigation of immune checkpoint inhibitors in the adjuvant setting
Track 21: Management of metastatic small cell lung cancer
Track 22: Novel agents under investigation for small cell lung cancer
Track 23: Emerging research aimed at enhancing the efficacy of immune checkpoint inhibitors

Interview with Jamie E Chaft, MD

Track 1: Case: A 54-year-old woman and never smoker presenting with arthralgias, digital clubbing and leg edema is diagnosed with Stage IIIA NSCLC and an EGFR exon 19 deletion
Track 2: Evaluation of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for NSCLC
Track 3: Predictors of clinical benefit from neoadjuvant therapy with immune checkpoint inhibitors
Track 4: Selection of patients for neoadjuvant therapy with anti-PD-1/PD-L1 antibodies
Track 5: Choice of adjuvant therapy for patients with NSCLC and an EGFR tumor mutation
Track 6: Risks and benefits with osimertinib in the adjuvant setting
Track 7: Status of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage lung cancer
Track 8: Results of the Phase III SELECT trial of adjuvant erlotinib for resected NSCLC with an EGFR tumor mutation
Track 9: Case: A 59-year-old man and former smoker with unresectable, Stage III NSCLC receives durvalumab as consolidation therapy after chemoradiation therapy
Track 10: Management of superior vena cava syndrome in patients with lung cancer
Track 11: Activity and tolerability of durvalumab as consolidation therapy
Track 12: Perspective on the results of the PACIFIC trial of durvalumab after chemoradiation therapy for Stage III NSCLC
Track 13: Recognition and management of pneumonitis associated with durvalumab/radiation therapy
Track 14: Impact of baseline steroids on the efficacy of PD-1/PD-L1 blockade in patients with NSCLC
Track 15: Effects of tumor mutations and PD-L1 expression on response to checkpoint inhibitors
Track 16: Case: A 68-year-old woman and smoker experiences recurrent colitis after receiving nivolumab for metastatic NSCLC
Track 17: Incidence and mitigation of diarrhea and colitis associated with checkpoint inhibitors
Track 18: Management of metastatic nonsquamous NSCLC in the first-line setting
Track 19: Perspective on the results of the Phase III IMpower150 study
Track 20: Selection of first-line therapy for patients with metastatic squamous NSCLC
Track 21: Risks and benefits of nivolumab with ipilimumab for metastatic NSCLC
Track 22: Therapeutic approach for patients with metastatic small cell lung cancer
Track 23: Duration of therapy with immune checkpoint inhibitors
Track 24: Pseudoprogression and hyperprogression associated with immune checkpoint inhibitors
Track 25: Case: A 64-year-old woman with metastatic NSCLC and an ALK rearrangement receives alectinib after developing intolerance to crizotinib
Track 26: Efficacy and side effects of the ALK inhibitors alectinib, brigatinib and lorlatinib
 
FACULTY
 
Suresh S Ramalingam, MD
Roberto C Goizueta Chair for
Cancer Research
Assistant Dean for Cancer Research
Deputy Director
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
 
Jamie E Chaft, MD
Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida